参考文献[1
ThaiAA, SolomonBJ, SequistLV，et al. Lung cancer [J]. Lancet，2021，398(10299):535-554. .
[2
FriedlaenderA, AddeoA, RussoA，et al. Targeted therapies in early stage NSCLC：hype or hope?[J]. Int J Mol Sci，2020，21(17):6329. .
[3
DongRF, ZhuML, LiuMM，et al. EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC：from molecular mechanisms to clinical research[J]. Pharmacol Res，2021，167:105583. .
[4
MasoodA, KanchaRK, SubramanianJ. Epidermal growth factor receptor（EGFR）tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations：focus on afatinib[J]. Semin Oncol，2019，46(3):271-283. .
[5
CooperAJ, SequistLV, LinJJ. Third-generation EGFR and ALK inhibitors：mechanisms of resistance and management[J]. Nat Rev Clin Oncol，2022，19(8):499-514. .
[6
LeonettiA, SharmaS, MinariR，et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer[J]. Br J Cancer，2019，121(9):725-737. .
[7
JännePA, YangJC, KimDW，et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer[J]. N Engl J Med，2015，372(18):1689-1699. .
[8
GossG, TsaiCM, ShepherdFA，et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer（AURA2）：a multicentre，open-label，single-arm，phase 2 study[J]. Lancet Oncol，2016，17(12):1643-1652. .
[9
PapadimitrakopoulouVA, MokTS, HanJY，et al. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor：AURA3 overall survival analysis[J]. Ann Oncol，2020，31(11):1536-1544. .
[10]
ChengY, HeY, LiW，et al. Osimertinib versus comparator EGFR TKI as First-Line treatment for EGFR-mutated advanced NSCLC：FLAURA China，a randomized study[J]. Target Oncol，2021，16(2):165-176. .
[11]
WuYL, TsuboiM, HeJ，et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer[J]. N Engl J Med，2020，383(18):1711-1723. .
[12]
MuY, HaoX, XingP，et al. Acquired resistance to osimertinib in patients with non-small-cell lung cancer：mechanisms and clinical outcomes[J]. J Cancer Res Clin Oncol，2020，146(9):2427-2433. .
[13]
SongY, JiaZQ, WangY，et al. Potential treatment strategy for the rare osimertinib resistant mutation EGFR L718Q [J]. J Thorac Dis，2020，12(5):2771-2780..
[14]
DuX, YangB, AnQ，et al. Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors[J]. Innovation（Camb），2021，2(2):100103. .
[15]
MeloskyB, Wheatley-PriceP, JuergensRA，et al. The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer[J]. Lung Cancer，2021，160:136-151. .
[16]
WangQ, YangS, WangK，et al. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer[J]. J Hematol Oncol，2019，12(1):63. .
[17]
DziadziuszkoR, SmitEF, DafniU，et al. Afatinib in NSCLC with HER2 mutations：results of the prospective，open-label phase Ⅱ NICHE trial of European Thoracic Oncology Platform（ETOP）[J]. J Thorac Oncol，2019，14(6):1086-1094. .
[18]
HeJ, HuangZ, HanL，et al. Mechanisms and management of 3rd generation EGFRTKI resistance in advanced nonsmall cell lung cancer （review）[J]. Int J Oncol，2021，59(5):90..
[19]
VokesNI, ChambersE, NguyenT，et al. Concurrent TP53 mutations facilitate resistance evolution in EGFR mutant lung adenocarcinoma [J]. J Thorac Oncol，2022，17(6):779-792. .
[20]
ZhuL, ChenZ, ZangH，et al. Targeting c-Myc to overcome acquired resistance of EGFR mutant NSCLC cells to the third-generation EGFR tyrosine kinase inhibitor，osimertinib[J]. Cancer Res，2021，81(18):4822-4834. .
[21]
RichTA, ReckampKL, ChaeYK，et al. Analysis of cell-free DNA from 32，989 advanced cancers reveals novel co-occurring activating RET alterations and oncogenic signaling pathway aberrations[J]. Clin Cancer Res，2019，25(19):5832-5842. .
[22]
JóriB, SchatzS, KallerL，et al. Comparison of resistance spectra after first and second line osimertinib treatment detected by liquid biopsy[J]. Cancers（Basel），2021，13(12):2861. .
[23]
RudinCM, PoirierJT, ByersLA，et al. Molecular subtypes of small cell lung cancer：a synthesis of human and mouse model data[J]. Nat Rev Cancer，2019，19(5):289-297. .
[24]
SchoenfeldAJ, ChanJM, KubotaD，et al. Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer[J]. Clin Cancer Res，2020，26(11):2654-2663. .
[25]
QinQ, LiX, LiangX，et al. CDK4/6 inhibitor palbociclib overcomes acquired resistance to third-generation EGFR inhibitor osimertinib in non-small cell lung cancer（NSCLC）[J]. Thorac Cancer，2020，11(9):2389-2397. .
[26]
RebuzziSE, AlfieriR, La MonicaS，et al. Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC：review of the literature and future perspectives[J]. Crit Rev Oncol Hematol，2020，146:102820. .
[27]
WhiteMN, PiotrowskaZ, StirlingK，et al. Combining osimertinib with chemotherapy in EGFR-mutant NSCLC at progression[J]. Clin Lung Cancer，2021，22(3):201-209. .
[28]
WangN, WangL, MengX，et al. Osimertinib（AZD9291） increases radio-sensitivity in EGFR T790M non-small cell lung cancer[J]. Oncol Rep，2019，41(1):77-86. .
[29]
LiangXM, QinQ, LiuBN，et al. Targeting DNA-PK overcomes acquired resistance to third-generation EGFR-TKI osimertinib in non-small-cell lung cancer[J]. Acta Pharmacol Sin，2021，42(4):648-654. .
[30]
GuJ, YaoW, ShiP，et al. MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancers[J]. Cancer，2020，126(16):3788-3799. .
[31]
LeX, NilssonM, GoldmanJ，et al. Dual EGFR-VEGF pathway inhibition：a promising strategy for patients with EGFR-mutant NSCLC[J]. J Thorac Oncol，2021，16(2):205-215. .
[32]
MakukuR, KhaliliN, RaziS，et al. Current and future perspectives of PD-1/PDL-1 blockade in cancer immunotherapy[J]. J Immunol Res，2021，2021:6661406. .
[33]
FitzpatrickO, NaidooJ. Immunotherapy for stage Ⅲ NSCLC：durvalumab and beyond[J]. Lung Cancer（Auckl），2021，12:123-131. .
[34]
FengX, XuES. Alectinib and lorlatinib function by modulating EMT-related proteins and MMPs in NSCLC metastasis[J]. Bosn J Basic Med Sci，2021，21(3):331-338. .
[35]
WatanabeS, GotoY, YasudaH，et al. HSP90 inhibition overcomes EGFR amplification-induced resistance to third-generation EGFR-TKIs[J]. Thorac Cancer，2021，12(5):631-642. .
[36]
LiAM, BoichardA, FelipE，et al. New therapeutic approaches to overcoming resistant EGFR exon 20 alterations[J]. Crit Rev Oncol Hematol，2020，151:102990. .
[37]
WangM, YangJC, MitchellPL，et al. Sunvozertinib，a selective EGFR inhibitor for previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations [J]. Cancer Discov，2022，12(7):1676-1689..
[38]
RobichauxJP, LeX, VijayanR，et al. Structure-based classification predicts drug response in EGFR-mutant NSCLC[J]. Nature，2021，597(7878):732-737. .
[39]
ShiK, WangG, PeiJ，et al. Emerging strategies to overcome resistance to third-generation EGFR inhibitors[J]. J Hematol Oncol，2022，15(1):94. .
